MNG505
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.483
- ALLOGRAFT_REJECTION+0.478
- INTERFERON_ALPHA_RESPONSE+0.436
- INTERFERON_GAMMA_RESPONSE+0.410
- CHOLESTEROL_HOMEOSTASIS+0.406
- OXIDATIVE_PHOSPHORYLATION+0.380
- IL6_JAK_STAT3_SIGNALING+0.368
- UNFOLDED_PROTEIN_RESPONSE+0.368
- MYC_TARGETS_V1+0.365
- ANDROGEN_RESPONSE+0.344
Top 10 suppressed
- KRAS_SIGNALING_DN-0.154
- ESTROGEN_RESPONSE_LATE-0.098
- SPERMATOGENESIS-0.073
- PANCREAS_BETA_CELLS-0.072
- XENOBIOTIC_METABOLISM-0.030
- ESTROGEN_RESPONSE_EARLY-0.019
- APICAL_SURFACE-0.013
- COAGULATION+0.009
- MYOGENESIS+0.015
- BILE_ACID_METABOLISM+0.023
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.897 |
| 2 | BS_RD4D5F9F | Med | Medulloblastoma | 0.894 |
| 3 | 89BE4270-8300-424E-A248-A0B00C3F5C1A | — | — | 0.890 |
| 4 | 1B1E827B-A98A-465E-AC6F-448C076E829D | — | — | 0.889 |
| 5 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.888 |
| 6 | MNG415 | — | — | 0.887 |
| 7 | CCA161B9-1E9A-4F8C-8144-B32B5CF76ECC | — | — | 0.882 |
| 8 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.880 |
| 9 | EC7327B2-6767-4005-9C51-005957C1F923 | — | — | 0.878 |
| 10 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.483 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.478 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.436 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.406 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.368 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.368 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.365 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.344 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.308 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.295 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.292 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.277 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.268 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.258 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.246 | Inavolisib | — uncovered |
| APOPTOSIS | 0.238 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.235 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.233 | Inavolisib | — uncovered |